Evidence map›Paper›PMID 40798866›Full record

ArticleThe Journal of antimicrobial chemotherapy2025

Population pharmacokinetics of bictegravir in real-world people with HIV.

Pierre Ekobena, Myriam Briki, Kim Dao, Catia Marzolini, Pascal Andre, Thierry Buclin, Matthias Cavassini, Monia Guidi, Paul Thoueille, Swiss HIV Cohort Study

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of antimicrobial chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Pierre EkobenaService and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Myriam BrikiService and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Kim DaoService and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6033-3435
Catia MarzoliniService and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Pascal AndreService and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Thierry BuclinService and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-0639-5536
Matthias CavassiniService of Infectious Diseases, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0003-0933-7833
Monia GuidiService and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-6419-9317
Paul ThoueilleService and Laboratory of Clinical Pharmacology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.ORCID 0000-0002-2305-4277
Swiss HIV Cohort Study

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectivesBictegravir is an integrase strand transfer inhibitor widely prescribed due to its good efficacy and safety profile. Its pharmacokinetic (PK) profile has not been described in real-world settings yet. This study aimed to characterize bictegravir population PK in people with HIV (PWH) and to identify covariates affecting its disposition.

methodsBictegravir concentrations were obtained from PWH as part of a therapeutic drug monitoring (TDM) follow-up performed at the Lausanne University Hospital, Switzerland, between July 2019 and July 2024. Demographic data, clinical data and co-medications were recorded during the routine Swiss HIV Cohort Study (SHCS) visits. A population PK model was developed using a non-linear mixed-effect approach with Monolix®.

resultsA total of 708 steady-state plasma concentrations from 572 PWH were available for the analysis. A one-compartment model with first-order absorption and elimination best characterized bictegravir PK. Age and body weight were found to significantly affect bictegravir clearance, individuals of 51 years weighing 100 kg showing a 13% increase, and those aged 80 years weighing 70 kg a 11% decrease, relative to an individual weighing 70 kg and aged 51 years. These effects are not deemed clinically significant and do not warrant a clinical intervention.

conclusionsConsidering the good safety and efficacy profile of bictegravir, routine TDM is of limited value for bictegravir. However, TDM of bictegravir could be beneficial in case of suspected viral resistance or non-adherence, in special subpopulations (i.e. obese individuals and pregnant women), or to monitor drug-drug interactions.

Indexed as

Heterocyclic Compounds, 4 or More RingsHIV InfectionsHIV Integrase InhibitorsPyridonesAdultAgedAged, 80 and overAmidesCohort StudiesDrug MonitoringFemaleHeterocyclic Compounds, 3-RingHumansMaleMiddle AgedPiperazinesAmidesbictegravirHeterocyclic Compounds, 3-RingHeterocyclic Compounds, 4 or More RingsHIV Integrase InhibitorsPiperazinesPyridones

Identifiers

PMID40798866
PMCPMC12494133

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.